Megalin-mediated specific uptake of chitosan/siRNA nanoparticles in mouse kidney proximal tubule epithelial cells enables AQP1 gene silencing

Theranostics

Volumn 4, Issue 10, 2014, Pages 1039-1051

  Gao, Shan ^a,b   Hein, San ^a,c   Dagnæs Hansen, Frederik ^a   Weyer, Kathrin ^a   Yang, Chuanxu ^a   Nielsen, Rikke ^a   Christensen, Erik I ^a   Fenton, Robert A ^a   Kjems, Jørgen ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b Kunshan RNAi Institute   (China)

^c Water Security Corporation   (United States)

Author keywords

Aquaporin 1; Chitosan; Megalin; Optical imaging; Renal targeting; siRNA

Indexed keywords

AQP1 PROTEIN, MOUSE; AQUAPORIN 1; CHITOSAN; MEGALIN; NANOPARTICLE; SMALL INTERFERING RNA;

ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; CHEMISTRY; CYTOLOGY; DOG; ENDOCYTOSIS; EPITHELIUM CELL; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; KIDNEY PROXIMAL TUBULE; KNOCKOUT MOUSE; MDCK CELL LINE; METABOLISM; MOLECULAR WEIGHT; PHYSIOLOGY; PROCEDURES; RNA INTERFERENCE;

ANIMALS; AQUAPORIN 1; CHITOSAN; DOGS; ENDOCYTOSIS; EPITHELIAL CELLS; GENE KNOCKDOWN TECHNIQUES; KIDNEY TUBULES, PROXIMAL; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-2; MADIN DARBY CANINE KIDNEY CELLS; MICE, KNOCKOUT; MOLECULAR WEIGHT; NANOPARTICLES; ORGAN SPECIFICITY; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84906874032     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.7866     Document Type: Article

References (49)

1. Dolman ME, Harmsen S, Storm G, Hennink WE, Kok RJ. Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells. Adv Drug Deliv Rev 2010;62:1344-1357.
2. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006;17:2974-2984.
3. Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther 2012;20:513-524.
4. Bramsen JB, Kjems J. Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering. Front Genet 2012;3:154.
5. Zhang X, Shan P, Jiang D, Noble PW, Abraham NG, Kappas A, et al. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J Biol Chem 2004;279:10677-10684.
6. Lu PY, Xie F, Woodle MC. In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 2005;54:117-142.
7. Gao S, Dagnaes-Hansen F, Nielsen EJ, Wengel J, Besenbacher F, Howard KA, et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 2009;17:1225-1233.
8. Laursen MB, Pakula MM, Gao S, Fluiter K, Mook OR, Baas F, et al. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol Biosyst 2010;6:862-870.
9. Schyth BD, Bramsen JB, Pakula MM, Larashati S, Kjems J, Wengel J, et al. In vivo screening of modified siRNAs for non-specific antiviral effect in a small fish model: number and localization in the strands are important. Nucleic Acids Res 2012;40:4653-4665.
10. Lewis DL, Wolff JA. Systemic siRNA delivery via hydrodynamic intravascular injection. Adv Drug Deliv Rev 2007;59:115-123.
11. Stokman G, Qin Y, Racz Z, Hamar P, Price LS. Application of siRNA in targeting protein expression in kidney disease. Adv Drug Deliv Rev 2010;62:1378-1389.
12. Takabatake Y, Isaka Y, Mizui M, Kawachi H, Takahara S, Imai E. Chemically modified siRNA prolonged RNA interference in renal disease. Biochem Biophys Res Commun 2007;363:432-437.
13. Hamar P, Song E, Kokeny G, Chen A, Ouyang N, Lieberman J. Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2004;101:14883-14888.
14. Nawroth I, Alsner J, Behlke MA, Besenbacher F, Overgaard J, Howard KA, et al. Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFalpha prevents radiation-induced fibrosis. Radiother Oncol 2010;97:143-148.
15. Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, Kjems J. Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 2009;17:162-168.
16. Yuan ZX, Zhang ZR, Zhu D, Sun X, Gong T, Liu J, et al. Specific renal uptake of randomly 50% N-acetylated low molecular weight chitosan. Mol Pharm 2009;6:305-314.
17. Weyer K, Storm T, Shan J, Vainio S, Kozyraki R, Verroust PJ, et al. Mouse model of proximal tubule endocytic dysfunction. Nephrol Dial Transplant 2011;26:3446-3451.
18. Gao S, Nielsen BS, Krogdahl A, Sorensen JA, Tagesen J, Dabelsteen S, et al. Epigenetic alterations of the SERPINE1 gene in oral squamous cell carcinomas and normal oral mucosa. Genes Chromosomes Cancer 2010;49:526-538.
19. Terris J, Ecelbarger CA, Nielsen S, Knepper MA. Long-term regulation of four renal aquaporins in rats. Am J Physiol 1996;271:F414-F422.
20. Hoffert JD, Fenton RA, Moeller HB, Simons B, Tchapyjnikov D, McDill BW, et al. Vasopressin-stimulated increase in phosphorylation at Ser269 potentiates plasma membrane retention of aquaporin-2. J Biol Chem 2008;283:24617-24627.
21. Moestrup SK, Nielsen S, Andreasen P, Jorgensen KE, Nykjaer A, Roigaard H, et al. Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes. J Biol Chem 1993;268:16564-16570.
22. Yuan ZX, Sun X, Gong T, Ding H, Fu Y, Zhang ZR. Randomly 50% N-acetylated low molecular weight chitosan as a novel renal targeting carrier. J Drug Target 2007;15:269-278.
23. Yuan ZX, Li JJ, Zhu D, Sun X, Gong T, Zhang ZR. Enhanced accumulation of low-molecular-weight chitosan in kidneys: a study on the influence of N-acetylation of chitosan on the renal targeting. J Drug Target 2011;19:540-551.
24. Park K, Kim JH, Nam YS, Lee S, Nam HY, Kim K, et al. Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control Release 2007;122:305-314.
25. Bramsen JB, Laursen MB, Nielsen AF, Hansen TB, Bus C, Langkjaer N, et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 2009;37:2867-2881.
26. Christensen EI, Birn H, Storm T, Weyer K, Nielsen R. Endocytic receptors in the renal proximal tubule. Physiology (Bethesda) 2012;27:223-236.
27. Shimizu H, Fujita T. New short interfering RNA-based therapies for glomerulonephritis. Nat Rev Nephrol 2011;7:407-415.
28. Wan X, Fan L, Hu B, Yang J, Li X, Chen X, et al. Small interfering RNA targeting IKKbeta prevents renal ischemia-reperfusion injury in rats. Am J Physiol Renal Physiol 2011;300:F857-F863.
29. Hauser PV, Pippin JW, Kaiser C, Krofft RD, Brinkkoetter PT, Hudkins KL, et al. Novel siRNA delivery system to target podocytes in vivo. PLoS One 2010;5:e9463.
30. Choi CH, Zuckerman JE, Webster P, Davis ME. Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci U S A 2011;108:6656-6661.
31. Zuckerman JE, Choi CH, Han H, Davis ME. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci U S A 2012;109:3137-3142.
32. Yuan H, Lanting L, Xu ZG, Li SL, Swiderski P, Putta S, et al. Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes. Am J Physiol Renal Physiol 2008;295:F605-F617.
33. Molitoris BA, Dagher PC, Sandoval RM, Campos SB, Ashush H, Fridman E, et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 2009;20:1754-1764.
34. Khan A, Benboubetra M, Sayyed PZ, Ng KW, Fox S, Beck G, et al. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target 2004;12:393-404.
35. Rao SB, Sharma CP. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. J Biomed Mater Res 1997;34:21-28.
36. Aspden TJ, Mason JD, Jones NS, Lowe J, Skaugrud O, Illum L. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci 1997;86:509-513.
37. Duceppe N, Tabrizian M. Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery. Expert Opin Drug Deliv 2010;7:1191-1207.
38. Kim JH, Kim YS, Park K, Lee S, Nam HY, Min KH, et al. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release 2008;127:41-49.
39. Sawai K, Mahato RI, Oka Y, Takakura Y, Hashida M. Disposition of oligonucleotides in isolated perfused rat kidney: involvement of scavenger receptors in their renal uptake. J Pharmacol Exp Ther 1996;279:284-290.
40. Zhai XY, Nielsen R, Birn H, Drumm K, Mildenberger S, Freudinger R, et al. Cubilin-and megalin-mediated uptake of albumin in cultured proximal tubule cells of opossum kidney. Kidney Int 2000;58:1523-1533.
41. Moestrup SK, Cui S, Vorum H, Bregengard C, Bjorn SE, Norris K, et al. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 1995;96:1404-1413.
42. Naeye B, Deschount H, Caveliers V, Descamps B, Braeckmans K, Vanhove C, et al. In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier. Biomaterials 2013; 34:2350-2358.
43. Thompson JD, Kornbrust DJ, Foy JW, Solano EC, Schneider DJ, Feinstein E, et al. Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration. Nucleic Acid Ther 2012; 22:255-264.
44. Ruggiero A, Villa CH, Bander DA, Rey M, Bergkvist M, Batt CA, et al. Paradoxical glomerular filtration of carbon nanotubes. Proc.Natl.Acad.Sci.U.S.A 2010;107: 12369-12374.
45. Cui S, Verroust PJ, Moestrup SK, Christensen EI. Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am J Physiol 1996;271:F900-F907.
46. Birn H, Fyfe JC, Jacobsen C, Mounier F, Verroust PJ, Orskov H, et al. Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. J Clin Invest 2000;105:1353-1361.
47. Tamma G, Procino G, Svelto M, Valenti G. Cell culture models and animal models for studying the patho-physiological role of renal aquaporins. Cell Mol Life Sci 2011.
48. Moeller HB, Fenton RA. Cell biology of vasopressin-regulated aquaporin-2 trafficking. Pflugers Arch 2012;464:133-144.
49. Fenton RA, Knepper MA. Mouse models and the urinary concentrating mechanism in the new millennium. Physiol Rev 2007;87:1083-1112.